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Abstract
Background: Oxidative stress has been proposed to be involved in the pathogenesis of Parkinson’s disease (PD).
A plausible source of oxidative stress in nigral dopaminergic neurons is the redox reactions that specifically involve
dopamine and produce various toxic molecules, i.e., free radicals and quinone species. a-Synuclein, a protein found
in Lewy bodies characteristic of PD, is also thought to be involved in the pathogenesis of PD and point mutations
and multiplications in the gene coding for a-synuclein have been found in familial forms of PD.
Results: We used dopaminergic human neuroblastoma BE(2)-M17 cell lines stably transfected with WT or A30P
mutant a-synuclein to characterize the effect of a-synuclein on dopamine toxicity. Cellular toxicity was analyzed by
lactate dehydrogenase assay and by fluorescence-activated cell sorter analysis. Increased expression of either wild-
type or mutant a-synuclein enhances the cellular toxicity induced by the accumulation of intracellular dopamine
or DOPA.
Conclusions: Our results suggest that an interplay between dopamine and a-synuclein can cause cell death in a
neuron-like background. The data presented here are compatible with several models of cytotoxicity, including the
formation of a-synuclein oligomers and impairment of the lysosomal degradation.
Background
Parkinson’s disease (PD) is a common neurodegenera-
tive disorder characterized by symptoms that include
resting tremor, slowness of movement, rigidity and pos-
tural imbalance. PD is a chronic and progressive disease
caused by degeneration of several neuronal populations
in the brain, most notably the dopaminergic neuromela-
nin-containing neurons of the substantia nigra (SN)
pars compacta [1].
While the etiopathogenesis of idiopathic PD remains
poorly understood, post mortem studies support the
involvement of oxidative stress and the production of
reactive oxygen species in neuronal damage [2,3]. Redox
reactions that specifically involve dopamine (DA) are a
possible source of oxidative stress accounting for the
more pronounced degeneration of dopaminergic neu-
rons in PD. A critical determinant of DA toxicity is the
amount of DA present in the cytoplasm, outside of the
acidic stabilizing environment of the synaptic vesicles
where the neurotransmitter is normally confined. In the
cytoplasm, DA can undergo both spontaneous or enzy-
matic-mediated oxidation and, as a consequence, gener-
ate superoxide anions, hydrogen peroxide and quinones
[4], which can damage cellular components such as
lipids, proteins and DNA [5-8].
Neuropathologically, PD is characterized by the pre-
sence of intracellular ubiquitinated inclusions, known as
Lewy bodies, composed predominantly of fibrillar
a-synuclein [9,10]. The discovery of three different mis-
sense mutations in the SNCA gene that codes for the
a -synuclein protein, found in rare familial forms of PD
indicates that a-synuclein is a likely causal factor in the
pathogenesis of PD [11-13]. Further supporting this con-
tention, multiplications of the SNCA gene are also cau-
sal for PD, suggesting that simply increasing the amount
of protein is sufficient to trigger the disease [14].
Human a-synuclein is a small, 140-residue, natively
unfolded protein abundantly expressed in neurons,
where it is localized at presynaptic terminals [15-18].
The physiological role of a-synuclein is still poorly
understood. Possible key functions of the protein could
be the modulation of synaptic vesicle recycling, DA sto-
rage and release at nerve terminals [19-24]. In addition,
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through interactions with proteins that regulate DA
synthesis and uptake, such as tyrosine hydroxylase [25],
the aromatic amino acid decarboxylase [26] and plasma
membrane dopamine transporter [27-29].
To explore the possibility of a synergistic effect
between oxidative cellular conditions induced by the
oxidation of DA and a-synuclein in PD, we investigated
how wild-type (WT) a-synuclein or its A30P pathogenic
mutant influences DA toxicity in a dopaminergic human
neuroblastoma BE(2)-M17 cell model stably over-
expressing a-synuclein.
Methods
Human Neuroblastoma Cell Lines
The production of stable cell lines overexpressing
a-synuclein from parental BE(2)-M17 human dopami-
nergic neuroblastoma cells has been described elsewhere
[30]. Cells were cultured in high-glucose DMEM (Life
Technologies) supplemented with 10% FBS, 50 U/ml
penicillin, 50 μg/ml streptomycin and 500 μg/ml G418.
a-Synuclein expression was evaluated by Western blot
analysis, using monoclonal anti-a-synuclein antibodies
(BD Biosciences), after cell lysis and protein separation
on SDS-PAGE. Films were analyzed with ImageJ (Ras-
band, W.S., ImageJ, U.S. National Institutes of Health,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/) for
densitometry quantification and protein levels were nor-
malized with respect to b-actin.
Lactate dehydrogenase (LDH) activity-based cytotoxicity
assay
Cells were plated in 96 well plates at 1.5 × 10
4 cells per
well in 100 μl of OptiMEM growth medium (Life Tech-
nologies) supplemented with DA or DOPA between
25 and 200 μM. Hydrogen peroxide generated by extra-
cellular catecholamine oxidation was removed by adding
600 U/ml catalase (Sigma-Aldrich). After 24 hr of incu-
bation, LDH activity measurements were performed
using a commercially available assay (Roche Applied
Science) according to the manufacturer’s instructions.
The ratio of LDH activity in the supernatant to the total
LDH activity was taken as the percentage of cell death.
For each experiment, eight wells per concentration were
averaged and each experiment was performed in
triplicate.
Fluorescence-activated cell sorter (FACS) analysis
After 24 hr of incubation in the presence of 200 μMD A
or DOPA, 10
6 cells/ml were labeled with Hoechst 33342
and propidium iodide (Vybrant Apoptosis Assay Kit #5;
Molecular Probes, Invitrogen), according to manufac-
turer’s specifications. Cells were analyzed using a dual-
laser FACSVantage SE flow cytometer (Becton
Dickinson, Mountain View, CA, USA). Propidium iodide
was excited using a 488-nm laser light and the emission
captured with a bandpass filter set at 613 ± 20 nm.
Hoechst 33342 was excited using a 351-nm ultraviolet
laser light and its emission captured with a bandpass fil-
ter set at 450 ± 20 nm. Cell Quest Acquisition and Ana-
lysis software (Becton Dickinson) was used to acquire
and quantify the fluorescence signal intensities and to
graph the data as bivariate dot density plots.
Statistical analysis
Data were analyzed using GraphPad Prism 4 software
and are expressed as the mean ± SEM. One-way
ANOVA followed by Newman-Keuls’s post hoc test was
used to determine whether groups were statistically dif-
ferent. P values < 0.05 were considered significant.
Results
To study the relationship between a-synuclein and cate-
cholamine toxicity, we used dopaminergic human neu-
roblastoma BE(2)-M17 cell lines stably transfected with
WT or A30P mutant a-synuclein, as previously
described [30]. The expression levels of WT and A30P
a-synuclein were, respectively, about 8 and 6 times
higher than cells transfected with the empty vector
(Figure 1). Each cell line (empty vector control, WT or
A30P a-synuclein) was treated with increasing concen-
trations (25, 50, 100 and 200 μM) of DA or DOPA, the
cellular precursor of DA, and the levels of cellular toxi-
city were determined using an LDH assay. To limit the
analysis only to the intracellular effects of DA or DOPA
oxidation, we added 600 U/ml of catalase in the growth
Figure 1 Expression levels of a-synuclein in stably transfected
M17 cell line. Immunoblot of a-synuclein in cell lines
overexpressing WT or A30P a-synuclein using a monoclonal
antibody against a-synuclein (upper panel). The same immunoblot
was then stripped and reprobed with an antibody for b-actin (lower
panel). Quantitation of a-synuclein is expressed as a ratio between
the major a-synuclein band and b-actin. Cells transfected with
vector alone show moderate expression of a-synuclein compared
to cells overexpressing WT or A30P a-synuclein.
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[31,32]. As expected, the presence of DA or DOPA in
the growth medium induced cellular damage in all cell
lines. The level of cell death was approximately 15% in
t h ep r e s e n c eo ft h eh i g h e s t amount of catecholamines
used in these experiments (200 μM) (Figure 2). Cells
overexpressing WT or A30P a-synuclein showed an
increased vulnerability to DA or DOPA-mediated toxi-
city (Figure 2), with a level of cellular death up to
~ 25% compared to controls. The toxicity induced by
DA or DOPA was similar.
T oc o n f i r mt h a to v e r e x p r e s s i o no fa-synuclein
increases cell vulnerability to DA or DOPA, we per-
formed analysis by fluorescence-activated cell sorting to
discriminate between necrosis and apoptosis [33]. The
analysis of 2 × 10
4 cells, obtained after 24 hr of incuba-
tion in the presence of 200 μMD Ao rD O P A ,i ss h o w n
in additional file 1. Figure 3 summarizes the results
derived from 4 independent experiments. Addition of
DA or DOPA to cells transfected with empty vector
increased both apoptotic and necrotic events with a
decrease in viability from 89% (control) to 62% (DA)
and to 70% (DOPA). Although the cellular growth rate
was similar both for empty vector and a-synuclein over-
expressing cells, the presence of WT or A30P a-synu-
clein had cytotoxic effects with a decrease in viability
from 89% to 66% (WT) and to 73% (A30P). The overex-
pression of WT or A30P a-synuclein variants also
increased cellular susceptibility to DA or DOPA, espe-
cially for apoptotic cell death. The viability of cells over-
expressing WT a-synuclein decreased from 89% to 32%
(DA) and to 26% (DOPA), with and a change in viability
of 57% and 63%, respectively. In the case of A30P over-
expression, viability decreased from 89% to 39% (DA)
and to 43% (DOPA), with a change in viability of 50%
and 46%, respectively. Results obtained for each
Figure 2 a-Synuclein exacerbates DA or DOPA toxicity in M17 cells. Overexpression of WT or A30P a-synuclein produces increased
sensitivity to DA or DOPA. Cells were exposed to increasing concentration of catecholamines for 24 hr and cytotoxicity was subsequently
estimated using the LDH assay (see Experimental Procedures). Cell lines included cells transfected with EV, WT or A30P a-synuclein. For each
experiment, eight wells per concentration were used and each experiment was performed in triplicate. Values are the mean ± SEM. * p < 0.05
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suggest that the cytotoxicity of a-synuclein and DA/
DOPA are greater than the sum of the individual effects.
Discussion
Oxidative stress and a-synuclein are considered two
potential factors involved in the pathogenesis of PD. An
important source of oxidative species is cytoplasmic DA
which may contribute to the preferential neuronal death
of catecholaminergic neurons observed in PD [34]. Pre-
vious studies have shown a direct correlation between
a-synuclein and oxidized DA. In cell-free systems, oxi-
dized DA can covalently modify a-synuclein and pro-
mote the stabilization of toxic protofibrils [35].
Moreover, degradation of a-synuclein through the cha-
perone-mediated autophagic pathway is impaired when
the protein is modified by oxidized DA [36].
In the present work, we explored the combined effects
of a-synuclein and DA in promoting cellular toxicity.
The influence of a-synuclein on DA toxicity has been
previously been mainly studied in transiently transfected
cells or under inducible expression conditions [37-41].
In this study, we used stable transfected dopaminergic
human neuroblastoma BE(2)-M17 cell lines expressing
WT or A30P a-synuclein [30]. We found that the pre-
sence of either WT or mutant a-synuclein increase sus-
ceptibility to oxidative conditions induced by DA in this
model.
Increased susceptibility to oxidative conditions upon
WT or mutant a-synuclein overexpression is in agree-
ment with studies using transient overexpresssion or
inducible cell lines [37-41], but are in contrast with one
previous study carried out using WT a-synuclein stably
transfected SH-SY5Y cells [32]. The observed discre-
pancy is unlikely to be due to the fact that different cell
lines were used as SY5Y cells have previously been
shown to be susceptible to toxic effects of a-synuclein
in a dopamine-dependent manner [38] but may be due
to the choice of cytotoxicity assays, as catecholamines
have been shown to interfere with MTT assay [32].
Because of this potential concern about interference of
catecholamines with colorimetric assays, we used FACS
analysis to confirm results seen in LDH release assays.
This method allowed us to confirm that DA exposure
and a-synuclein expression have additive toxic effects.
One possible interpretation for two observations
described in this study, the toxicity measured in cells
over expressing both WT and A30P a-synuclein relative
to the control and the synergistic toxicity of a-synuclein
and DA is that a-synuclein may have an effect on DA
metabolism. It has previously been reported that overex-
pression of WT or mutant a-synuclein in PC12 cells
[42] or in differentiated MESC2.10 cells [22], increases
Figure 3 DA and DOPA augment a-synuclein mediated
apoptosis and necrosis. Decreased cell viability (A) induced by DA
or DOPA is accompanied by increased apoptosis (B) and necrosis
(C). After 24 hr of incubation in the presence of 200 μMD Ao r
DOPA, cells were labeled with Hoechst 33342 and propidium iodide
and analyzed by FACS. For each experiment, 1.5-3 × 10
4 cells were
analyzed. Values are the mean ± SEM (n = 4). * p < 0.05,
** p < 0.01, *** p < 0.001 relative to EV.
Table 1 Cell viability determined by FACS measurements
EV WT A30P
CNTR 89% ± 2% 66% ± 4% 73% ± 4%
DA 62% ± 4% 32% ± 8% 39% ± 5%
DOPA 70% ± 4% 30% ± 7% 43% ± 3%
FACS measurements were carried out on cells transfected with empty vector
(EV), WT or A30P a-synuclein variants, after 24 hr of incubation in the absence
(CNTR) or in the presence of 200 μM DA or DOPA.
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levels of cytosolic DA in adrenal chromaffin cells from
mice over expressing human a-synuclein or from
knock-out mice are unaltered compared to wild type
animals [42,43], suggesting that the observation of the
DA homeostasis effect by a-synuclein may be influenced
by cell line. As we have not directly measured cytoplas-
mic DA concentrations in this cell line, further experi-
ments are needed to define whether a-synuclein affects
DA homeostasis in this context.
Another possible mechanism that may contribute to
the combined toxic effects of a-synuclein and DA is the
interaction between a-synuclein and the oxidation pro-
ducts of DA. In support of this hypothesis, we have
shown in vitro that a-synuclein is able to incorporate
radiolabeled DA [44]. The mechanism(s) underlying the
potentially toxic effects of DA-modified a-synuclein are
unclear. One leading hypothesis is that quinone adducts
of a-synuclein may stabilize protofibrils [35]. Addition-
ally, DA-modified a-synuclein blocks degradation of
long-lived by chaperone mediated autophagy [36], an
effect that can be seen with A30P a-synuclein without
the incubation of the protein with DA [45]. Therefore,
both impairment of the autophagy degradation and the
formation of a-synuclein oligomers may both contribute
to the observed cytotoxicity. Detergent-stable a-synu-
clein oligomers can isolated from DA-treated cells [41]
and non-denaturing size fractionation also identifies
non-covalent oligomers of a-synuclein in catecholami-
nergic cells [38]. However, whether these oligomers are
specific to DA treatment, and therefore the same as the
putative toxic species seen in vitro, is difficult to test as
DA-modified a-synuclein has not yet been shown to be
stable enough to be detected in vivo.F u r t h e rw o r ki s
therefore needed to establish whether the effects of DA
and a-synuclein are mediated through direct interaction
or independent pathways.
Conclusions
In summary, we have shown that DA exposure increases
the toxicity of the PD-related protein a-synuclein in
dopaminergic neuroblastoma cell lines BE(2)-M17.
These results support the concept that DA, likely
through formation of cytosolic quinones, has synergistic
toxic effects with a-synuclein. While additional studies
are required to define the precise mechanism(s) by
which the two stressors act in a cellular context, our
results further highlight that an interaction between
cytosolic DA and a-synuclein may underlie the suscept-
ibility of SN neurons in PD.
Additional file 1: Figure S1. DA or DOPA induced toxicity analyzed
by FACS. After 24 hrs of incubation in the presence of 200 mM DA or
DOPA, cells were labeled with Hoechst 33342 and propidium iodide. 2 ×
104 cells were analyzed for each condition tested. The staining pattern
resulting from simultaneous use of these dyes makes it possible to
distinguish viable, apoptotic and necrotic cell populations. Cells
transfected with the empty vector (A1-3) show moderate increase of
apoptosis and necrosis after the incubation with either catecholamine.
Apoptosis strongly increases in cell lines overexpressing both WT (B1-3)
and A30P (C1-3) asyn variants. Necrosis is also increased after exposure
to DA or DOPA, but to a lesser extent. Ap: apoptotic cells; N: necrotic
cells; V: viable cells.
Abbreviations
DA: dopamine; FACS: fluorescence-activated cell sorter; LDH: lactate
dehydrogenase; MTT: [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide]; PD: Parkinson’s disease; WT: wild-type.
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